MRNA-5671

mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna. It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene.

It is currently being evaluated for the treatment of either non-small cell lung cancer, colorectal cancers with microsatellite instability, or pancreatic adenocarcinoma, all with confirmed KRAS driver mutations. In 2021 Merck dropped the trial, and clinicaltrials.gov study NCT03948763 ended on August 25, 2022. As of May 2024, no further progress on this vaccine has been announced.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1364489518 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.